 |
|
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):841-850. Published online 2022 Sep 19 DOI: https://doi.org/10.3350/cmh.2022.0239
|
|
Citations to this article as recorded by
 The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today
Václav Šmíd, Karel Dvořák
Vnitřní lékařství.2024; 70(1): E8. CrossRef A global action agenda for turning the tide on fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Quentin M. Anstee, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Grac
Hepatology.2024; 79(2): 502. CrossRef Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
Annals of Hepatology.2024; 29(1): 101153. CrossRef Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone
Metabolism.2024; 151: 155721. CrossRef Reply
Jong Woo Hahn, Soeun Kim, Dong Keon Yon
Clinical Gastroenterology and Hepatology.2024; 22(4): 905. CrossRef Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan Gray
The American Journal of the Medical Sciences.2024; 367(2): 77. CrossRef Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease
Peng‐sheng Ting, Wei‐Ting Lin, Chiung‐Kuei Huang, Hui‐Yi Lin, Tung‐Sung Tseng, Po‐Hung Chen
Alcohol: Clinical and Experimental Research.2024; 48(1): 88. CrossRef Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald
The Lancet Gastroenterology & Hepatology.2024; 9(2): 159. CrossRef Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
Mislav Barisic-Jaman, Marko Milosevic, Viktoria Skurla, David Dohoczky, Josip Stojic, Petra Dinjar Kujundzic, Maja Cigrovski Berkovic, Ana Majic-Tengg, Ana Matijaca, Tomo Lucijanic, Mirjana Kardum-Pejic, Vlatka Pandzic Jaksic, Srecko Marusic, Ivica Grgure
Biomedicines.2024; 12(2): 323. CrossRef Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis
Reham Mohammed Dawood, Ghada Maher Salum, Mai Abd El-Meguid, Basma EL-sayed Fotouh
Journal of Interferon & Cytokine Research.2024; 44(3): 111. CrossRef Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe
Molecules.2024; 29(3): 709. CrossRef Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
Xiaoyan Wu, Yuzhou Shen, Yufei Meng, Jinsi Chen, Yongchen Zhang, Sheng Zeng, Huihui Xu
Life Sciences.2024; 341: 122498. CrossRef Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China
Run Zhou, Binbin Zhang, Wei Zhang, Tingting Kong, Jie Fu, Jie Li, Junping Shi
BMJ Open.2024; 14(2): e078333. CrossRef Updated Insights into Probiotics and Hepatobiliary Diseases
Xiaoyu Xu, Cheng Zhang, Guoyi Tang, Ning Wang, Yibin Feng
Biomedicines.2024; 12(3): 515. CrossRef Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study
Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha
Liver International.2024;[Epub] CrossRef Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography
Harish Gopalakrishna, Gayatri B. Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman
European Journal of Gastroenterology & Hepatology.2024; 36(4): 476. CrossRef Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Avneet Singh, Adam Buckholz, Sonal Kumar, Carolyn Newberry
Nutrients.2024; 16(5): 658. CrossRef Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283. CrossRef Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression
Ignazio S Piras, Johanna K DiStefano
Life Science Alliance.2024; 7(6): e202302517. CrossRef Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 235. CrossRef In response to: Steatotic liver disease-know your enemies
Michael H. Le, Linda Henry, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
Journal of Viral Hepatitis.2024;[Epub] CrossRef The impact of county-level food access on the mortality and post-transplant survival among patients with steatotic liver disease
Yutaka Endo, Diamantis I. Tsilimigras, Mujtaba Khalil, Jason Yang, Selamawit Woldesenbet, Kazunari Sasaki, Ashley Limkemann, Austin Schenk, Timothy M. Pawlik
Surgery.2024;[Epub] CrossRef Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Julieta Trinks, María F Mascardi, Adrián Gadano, Sebastián Marciano
World Journal of Gastroenterology.2024; 30(14): 1982. CrossRef Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608. CrossRef Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Min-Kyu Kang, Min-Cheol Kim
Medicina.2023; 59(2): 375. CrossRef The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
George Chen, Bubu Banini, Albert Do, Joseph K. Lim
Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease
Rongtao Lai, Mindie H. Nguyen
Clinical Gastroenterology and Hepatology.2023; 21(11): 2984. CrossRef The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Metabolites.2023; 13(5): 581. CrossRef The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women
Johanna K. DiStefano
Nutrients.2023; 15(12): 2670. CrossRef Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports.2023; 25(8): 151. CrossRef Cardiovascular outcomes among persons with HIV and nonalcoholic fatty liver disease
Sepiso K. Masenga, Lweendo Muchaili, Benson M. Hamooya
AIDS.2023; 37(8): 1329. CrossRef Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark
International Journal of Obesity.2023; 47(8): 677. CrossRef Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Amina Basha, Sarah C. May, Ryan M. Anderson, Niharika Samala, Raghavendra G. Mirmira
International Journal of Molecular Sciences.2023; 24(12): 9996. CrossRef Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
Ultrasonography.2023; 42(3): 421. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber-Sagi, Linda Henry, Lynn H. Gerber
Nature Reviews Gastroenterology & Hepatology.2023; 20(11): 708. CrossRef The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study
Matina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Stergios A. Polyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodorid
Metabolism.2023; 147: 155666. CrossRef The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
Ehsan Amini-Salehi, Soheil Hassanipour, Mohammad-Hossein Keivanlou, Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Azin Vakilpour, Farahnaz Joukar, Mohammad Hashemi, Nazila Sattari, Mohammadreza Javid, Fariborz Mansour-Ghanaei
Nutrition Reviews.2023;[Epub] CrossRef Ca2+ signaling and the Hippo pathway: Intersections in cellular regulation
Samar Sayedyahossein, Louise Thines, David B. Sacks
Cellular Signalling.2023; 110: 110846. CrossRef The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study
Matina Kouvari, Sophia C. Mylonakis, Angeliki Katsarou, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Michail Kokkorakis, Ornella Verrastro, Giulia Angelini, Georgios Markakis, Mohammed Eslam, Jacob George, Georgios Papatheodoridis, Geltrude Ming
Diabetes Research and Clinical Practice.2023; 203: 110870. CrossRef Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Aleksander Krag, Maria Buti, Jeffrey V. Lazarus, Alina M. Allen, Jacqueline Bowman, Patrizia Burra, Giacomo Donnini, Ajay Duseja, Manal H. El-Sayed, Amalia Gastaldelli, Ben Hainsworth, Tom H. Karlsen, Michael Kessler, Marko Korenjak, Henry E. Mark, Jake P
Journal of Hepatology.2023; 79(5): 1076. CrossRef Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review
Fateme Ziamanesh, Mehdi Mohammadi, Sholeh Ebrahimpour, Ozra Tabatabaei-Malazy, Asieh Mosallanejad, Bagher Larijani
Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1083. CrossRef Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019
Jie Li, Qingzhi Wang, Wenjing Ni, Chuan Liu, Zhihui Li, Xiaolong Qi
Global Transitions.2023; 5: 160. CrossRef The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry
Nasser Alorfi, Ahmed Ashour
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3115. CrossRef Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?
Chrysi Koliaki, Maria Dalamaga, Stavros Liatis
Current Obesity Reports.2023; 12(4): 514. CrossRef Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama
International Journal of Molecular Sciences.2023; 24(20): 15473. CrossRef An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Timothy J. Kendall, Maria Jimenez-Ramos, Frances Turner, Prakash Ramachandran, Jessica Minnier, Michael D. McColgan, Masood Alam, Harriet Ellis, Donald R. Dunbar, Gabriele Kohnen, Prakash Konanahalli, Karin A. Oien, Lucia Bandiera, Filippo Menolascina, An
Nature Medicine.2023; 29(11): 2939. CrossRef Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis
Tingting Kong, Yunpeng Gu, Lei Sun, Run Zhou, Jie Li, Junping Shi
Endocrine Journal.2023; 70(10): 959. CrossRef Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
Hepatology.2023; 78(6): 1858. CrossRef The Impact and Burden of Dietary Sugars on the Liver
Helaina E. Huneault, Ana Ramirez Tovar, Cristian Sanchez-Torres, Jean A. Welsh, Miriam B. Vos
Hepatology Communications.2023;[Epub] CrossRef Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area †
Tanmoy Mondal, Coleman I. Smith, Christopher A. Loffredo, Ruth Quartey, Gemeyel Moses, Charles D. Howell, Brent Korba, Bernard Kwabi-Addo, Gail Nunlee-Bland, Leanna R. Rucker, Jheannelle Johnson, Somiranjan Ghosh
International Journal of Molecular Sciences.2023; 24(23): 16654. CrossRef Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States
Pedro Ochoa-Allemant, Jorge A. Marrero, Marina Serper
Hepatology Communications.2023;[Epub] CrossRef The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review
Manpreet Kaur, Shanmathi Murugesan, Sachpreet Singh, Katherine N Uy, Jasjeet Kaur, Navina Mann, Rajneet K Sekhon
Cureus.2023;[Epub] CrossRef International diet quality index and revised diet quality index relationship with non-alcoholic fatty liver disease: a case-control study
Narjes Najibi, Mitra Kazemi Jahromi, Farshad Teymoori, Hossein Farhadnejad, Ammar Salehi-Sahlabadi, Parvin Mirmiran
BMC Gastroenterology.2023;[Epub] CrossRef Developmental Programming: Impact of Prenatal Exposure to Bisphenol A on Senescence and Circadian Mediators in the Liver of Sheep
Giuliana Motta, Soundara Viveka Thangaraj, Vasantha Padmanabhan
Toxics.2023; 12(1): 15. CrossRef Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
Chul-min Lee, Eileen L. Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun
Hepatology.2023;[Epub] CrossRef
|